Immuneering Corporation (IMRX)

NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that management will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, taking place virtually from February 25-26, 2026. Management, including Ben Zeskind, Chief Executive Officer, and Brett Hall, Chief Scientific Officer, will discuss the company's pipeline, platform, and business strategy.

Immuneering (NASDAQ: IMRX - Get Free Report) and GRI Bio (NASDAQ: GRI - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, profitability, valuation and earnings. Profitability This table compares Immuneering and GRI Bio's

Immuneering Corporation (NASDAQ: IMRX - Get Free Report) insider Brett Matthew Hall acquired 2,298 shares of the firm's stock in a transaction on Thursday, January 15th. The shares were acquired at an average price of $4.57 per share, with a total value of $10,501.86. Following the completion of the transaction, the insider directly owned 376,496 shares

Immuneering Corporation (NASDAQ: IMRX - Get Free Report) was the target of a large growth in short interest during the month of December. As of December 31st, there was short interest totaling 10,924,303 shares, a growth of 43.1% from the December 15th total of 7,635,854 shares. Based on an average trading volume of 1,780,211 shares, the

Immuneering Corporation remains a Strong Buy after 12-month OS data for atebimetinib + mGnP in 1st-line pancreatic cancer showed a robust 64% rate. IMRX's combination nearly doubles standard-of-care 12-month OS (64% vs. 35%), with a favorable safety profile and regulatory alignment for phase 3 initiation mid-2026. Market overreacted to the OS decline from 9 to 12 months; cross-trial comparisons are misleading and do not reflect the differentiated mechanism of IMRX's MEK inhibitor.

Immuneering Corporation (NASDAQ: IMRX) stock is trading lower on Thursday after the company shared updated data from its ongoing Phase 2a trial of atebimetinib (IMM-1-104) with a modified chemotherapy combination (gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer.

Immuneering Corporation (IMRX) Discusses Positive 12-Month Overall Survival Update From Phase IIa Trial of Atebimetinib in First-Line Pancreatic Cancer Transcript

- Reported 12-month overall survival (OS) in Phase 2a clinical trial nearly double the benchmark from pivotal study of standard of care gemcitabine/nab-paclitaxel (GnP) - - Atebimetinib consistently demonstrates impressive overall survival advantage at all time periods reported; Median overall survival remains unreached as of data cutoff, suggesting encouraging durability of clinical benefit - - Anticipate dosing first patient in pivotal Phase 3 clinical trial, MAPKeeper 301, in mid-2026 - - Company to host conference call at 4:30 p.m. ET today - NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced positive updated overall survival (OS) and safety data from its ongoing Phase 2a trial of atebimetinib (IMM-1-104) in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer patients (N=34), with over 13 months median follow up time.

Immuneering Corporation (NASDAQ: IMRX - Get Free Report) has been assigned an average rating of "Moderate Buy" from the eight analysts that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, six have assigned a buy rating and one has issued a strong buy rating on the company.

Immuneering (IMRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Janu

– End-of-Phase 2 interactions with FDA complete; scientific advice received from EMA – – Company expects to dose first patient in global Phase 3 registrational trial, MAPKeeper 301, in mid-2026 – – Overall survival update for Phase 2a trial of atebimetinib + mGnP in first-line pancreatic cancer patients planned in coming weeks – NEW YORK, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that it is on track to dose the first patient in its planned global Phase 3 registrational trial in first line pancreatic cancer patients in mid-2026, evaluating atebimetinib (320 mg QD) in combination with modified gemcitabine and nab-paclitaxel (mGnP), compared with gemcitabine and nab-paclitaxel (GnP) alone. Notably, the company completed its End-of-Phase 2 (EOP2) interactions with the U.S. Food and Drug Administration (FDA) and received scientific advice from the European Medicines Agency (EMA).

NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that it is expected to be added to the Nasdaq Biotechnology Index (“NBI”) (Nasdaq: NBI). Immuneering's addition will become effective prior to market open on Monday, December 22, 2025.

Shares of Immuneering Corporation (NASDAQ: IMRX - Get Free Report) have been given an average rating of "Moderate Buy" by the eight analysts that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, six have assigned a buy rating and one has assigned a strong buy rating to

Immuneering (IMRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

The mean of analysts' price targets for Immuneering (IMRX) points to a 126.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.